Bizarre Patents
A portable partition for use in an automobile having a seat with a seat bench and a seat backrest.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8133728 | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cell... | 03/13/2012 |
| 8129185 | Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Tr... | 03/06/2012 |
| 8076134 | CD4+CD25− T cells and Tr1-like regulatory T cells The invention provides CD4+CD25− T cells and Tr1-like regulatory T cells (i.e., contact-independent Type 1-like regulatory T cells), processes for their production and their use for regulatory purposes. ... | 12/13/2011 |
| 8076135 | Method of preparing a treatment effective amount of allogeneic T-cells Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation... | 12/13/2011 |
| 8076133 | Method for obtaining antigen-specific Tr1 regulatory lymphocytes The invention relates to a method for preparing antigen-specific Tr1 regulatory lymphocytes. The inventive method involves the use of artificial antigen-presenting cells expressing a molecule from the HLA class II system and a human LFA-3 molecule and expressing non... | 12/13/2011 |
| 8071374 | Methods for preparing T-cells for cell therapy T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradab... | 12/06/2011 |
| 8053235 | Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use The present invention provides methods for generating mammalian T cell populations comprising antigen-specific CD4+CD25+ regulatory T cells from freshly isolated CD4+CD25− T cells. The method comprises selecting CD4+CD25− T cells from a sample obtained from a ma... | 11/08/2011 |
| 8012750 | T-cell activation device A biodegradable device for activating T-cells includes a biodegradable support and a binder attached to the biodegradable support, the binder having reactivity to one or more agents capable of binding to a T-cell surface antigen. ... | 09/06/2011 |
| 7977095 | Generation and isolation of antigen-specific T cells The present invention relates generally to methods for generating, expanding, and isolating antigen-specific T cells. Compositions of antigen-specific T cells activated and expanded by the methods herein are further provided. ... | 07/12/2011 |
| 7972848 | Isolation and identification of cross-reactive T cells Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requiremen... | 07/05/2011 |
| 7910368 | Method of extended culture for antigen-specific cytotoxic lymphocytes The present invention is a method for inducing cytotoxic T cell having an antigen-specific cytotoxic activity, a method for maintaining the cell, a method for continuously culturing the cell or a method for expanding the cell, comprising the step of culturing a cyto... | 03/22/2011 |
| 7892828 | Method of identifying a MHC class I restricted T cell response Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses... | 02/22/2011 |
| 7678571 | Procedure for the large-scale T-lymphocytes culture in a homogeneous system The present invention refers to a procedure for the large-scale amplification of human lymphocytic cell lines for therapeutic use, consisting of a homogeneous culture system. The claimed invention also refers to the production of therapeutic doses of lymphocytic cel... | 03/16/2010 |
| 7678572 | Methods for preparing T-cells for cell therapy T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradab... | 03/16/2010 |
| 7575925 | Cell preparations comprising cells of the T cell lineage and methods of making and using them The invention relates to cell preparations comprising cells of the T cell lineage, methods for preparing same, and uses of the cell preparations. ... | 08/18/2009 |
| 7435592 | Compositions for allogeneic cell therapy A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune m... | 10/14/2008 |
| 7432253 | Phosphoepoxides, method for making same and uses The invention provides compounds comprising at least one phosphoepoxide group of the formula: where R1 is selected from among —CH3 and —CH2—CH3. Cat+... | 10/07/2008 |
| 7413868 | Use of particulate labels in bioanalyte detection methods New applications for the use of distinguishable particulate labels available in a variety of hues and sized in the submicron range are described. These applications include profiling of cellular components, obtaining secretion patterns, identifying a multiplicity of... | 08/19/2008 |
| 7405077 | Sperm protein 17 for the diagnosis and treatment of cancer The results herein identify Sp17 as a novel cancer-testis antigen in multiple myeloma. Sp17 recombinant protein was generated from E. coli. A CD8 predominant CTL line was generated that was able to lyse autologous targets in a Sp17-dependent HLA class I-restr... | 07/29/2008 |
| 7402431 | T-cell therapy formulation Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation... | 07/22/2008 |
| 7402432 | Process for producing T lymphocytes The present invention is directed to an in vitro method for producing T lymphocytes. The method involves culturing bone marrow cells on a matrix seeded with keratinocytes and fibroblasts. ... | 07/22/2008 |
| 7361479 | Assay The present invention provides a method of determining the presence or amount of newly synthesized antibody in a sample in response to an immunogen by detecting the released antibodies or parts thereof in a sample containing lymphocytes which have been disrupted whe... | 04/22/2008 |
| 7354762 | Method for producing CE7-specific redirected immune cells Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 04/08/2008 |
| 7344830 | Heteroduplex tracking assay A change in viral tropism occurs in many HIV positive individuals over time and may be indicated by a shift in coreceptor use from CCR5 to CXCR4. The shift in coreceptor use to CXCR4 has been shown to correlate with increased disease progression. In patients undergo... | 03/18/2008 |
| 7335351 | Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these pepti... | 02/26/2008 |
| 7332349 | Detection of cell membrane-associated proteins using membrane fragments displayed on encoded microparticle arrays Disclosed are methods relating to cell membrane fragments associated with microbeads, so that the characteristics of the cells the fragments originated from can be determined. The fragments can be oriented with what was the outer surface of the cell membrane facing ... | 02/19/2008 |
| 7320787 | Redirection of cellular immunity by protein tyrosine kinase chimeras Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerou... | 01/22/2008 |
| 7306927 | Method of inducing immunity against stratum corneum chymotrytic enzyme The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers,... | 12/11/2007 |
| 7282198 | Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these pepti... | 10/16/2007 |
| 7265209 | CE7-specific chimeric T cell receptor Genetically engineered, CE7-specific redirected immune cells expressing a cell surface protein having an extracellular domain comprising a receptor which is specific for CE7, an intracellular signaling domain, and a transmembrane domain, and methods of use for such ... | 09/04/2007 |
| 7262014 | Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g.... | 08/28/2007 |
| RE39788 | Gene therapy Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy. ... | 08/21/2007 |
| 7217567 | Method and formulation for lyophilizing cultured human cells to preserve RNA and DNA contained in cells for use in molecular biology experiments The present invention relates to methods for lyophilizing eukaryotic cells and isolating intact nucleic acids from such cells, and related kits for using the same. ... | 05/15/2007 |
| 7211411 | Human papilloma virus treatment Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disc... | 05/01/2007 |
| 7192769 | Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of antigen presenting cells and lymphoreticular stromal cells, and in the absence of exog... | 03/20/2007 |
| 7172900 | Isolated CD8T lymphocytes specifically cytotoxic for a disease causing target cell Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cell... | 02/06/2007 |
| 7166467 | Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apo... | 01/23/2007 |
| 7160723 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 01/09/2007 |
| 7157089 | Immune responses using compositions containing stress proteins The present invention relates to a vaccine for inducing an immune response to an antigen in a vertebrate (e.g., mammal) comprising an antigen and all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homolog... | 01/02/2007 |
| 7132243 | Clonal expansion of T cells of unknown specificity and identification of ligand recognized by the clonally expanded T cells A process for clonally expanding T cells of unknown specificity and a process for identifying a peptide ligand recognized by said T cells are provided. A process for clonally expanding T cells of unknown specificity which comprises co-culturing said T cells o... | 11/07/2006 |
